Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome ───────────────────────────────────────────────────────────────────────────────────── Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe Peeling Skin Syndrome Currently Has No Approved Treatment ASHBURN, Va., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome …
Open exhibit ↗Current Report · Items 7.01, 8.01, 9.01 · 8-K
Quoin Pharmaceuticals Ltd.
Regulation FD Disclosure · Other Events
Item 7.01. Regulation FD Disclosure. On September 22, 2026, Quoin Pharmaceuticals Ltd. (the “Company” or “Quoin”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to QRX003, the Company’s investigational product candidate, for the treatment of Peeling Skin Syndrome.…
Company context
Quoin Pharmaceuticals Ltd. Is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.